Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Leukemia Cutis As an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia

Mahmood B Aldapt, MD, Mohamed A Yassin, MBBS, MSc

Blood (2019) 134 (Supplement_1): 5461.

https://doi.org/10.1182/blood-2019-121654

Published: 2019

Journal Articles

Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome

Crystal Gao, Christopher McCormack, Carrie van der Weyden, Michelle S. Goh, Belinda A. Campbell, Robert Twigger, Odette Buelens, Simon J. Harrison, Christine Khoo, Stephen Lade, H. Miles Prince

Blood (2019) 134 (16): 1346–1350.

https://doi.org/10.1182/blood.2019000765

Published: 2019

Journal Articles

Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma

Blood (2018) 132 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2018-99-119861

Published: 2018

Journal Articles

Pirfenidone Reverses Murine Chronic Graft Versus Host Disease

Jing Du, Ryan P Flynn, PhD, Katelyn Paz, Ante Vulic, MD, Tara M. Robinson, MD PhD, Katie E Lineburg, BSc, Kelli P A Macdonald, PhD, Geoffrey R Hill, Jonathan S Serody, MD, Ivan Maillard, MD PhD, Angela Panoskaltsis-Mortari, PhD, Timothy Schacker, MD, Leo Luznik, MD, Bruce R. Blazar, MD

Blood (2016) 128 (22): 1158.

https://doi.org/10.1182/blood.V128.22.1158.1158

Published: 2016

Journal Articles

Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma

Fiona Child, MD, Pablo Ortiz Romero, Prof., Rute Alvarez, MD, Martine Bagot, Rudolf Stadler, MD, Michael Weichenthal, MD, Rosario Alves, MD, Maria Grazia Bernengo, Prof., Marie Beylot-Barry, Prof., Richard Cowan, Larisa J. Geskin, MD, Amparo Pérez Ferriols, Peter Hellemans, MD, Yusri Elsayed, MD, PhD, Charles Phelps, Ann Forslund, Makio Kamida, Pier Luigi Zinzani, MD

Blood (2012) 120 (21): 3676.

https://doi.org/10.1182/blood.V120.21.3676.3676

Published: 2012

Journal Articles

Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium

David A. Jacobsohn, Brenda F. Kurland, Joseph Pidala, Yoshihiro Inamoto, Xiaoyu Chai, Jeanne M. Palmer, Sally Arai, Mukta Arora, Madan Jagasia, Corey Cutler, Daniel Weisdorf, Paul J. Martin, Steven Z. Pavletic, Georgia Vogelsang, Stephanie J. Lee, Mary E. D. Flowers

Blood (2012) 120 (13): 2545–2552.

https://doi.org/10.1182/blood-2012-04-424135

Published: 2012

Includes: Supplemental data

Journal Articles

Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL)

David J. Straus, MD, Madeleine Duvic, MD, Steven M. Horwitz, MD, Kenneth B. Hymes, MD, Andre Goy, MD, Francisco J. Hernandez-Ilizaliturri, MD, Tatyana Feldman, MD, Brett Wegner, Patricia Myskowski, MD

Blood (2011) 118 (21): 882.

https://doi.org/10.1182/blood.V118.21.882.882

Published: 2011

Journal Articles

Comparison of Proposed NIH Response Criteria with Clinician-Reported Changes in Organ-Specific and Overall Response

Jeanne Palmer, MD, Stephanie J. Lee, MD, MPH, Xiaoyu Chai, MS, Barry Storer, PhD, Joseph Pidala, MD, MS, Corey S. Cutler, MD, MPH, FRCPC, Mukta Arora, MD, Mary E.D. Flowers, MD, Steven Z. Pavletic, MD, Georgia B. Vogelsang, MD, Yoshihiro Inamoto, MD, Madan Jagasia, MD, MS, Chen George, MD, Paul J. Martin, MD

Blood (2011) 118 (21): 1978.

https://doi.org/10.1182/blood.V118.21.1978.1978

Published: 2011

Journal Articles

Selective Targeting of B Cells with Mesenchymal Stromal Cells Treatment Is An Efficacious Strategy for Cutaneous Cgvhd,

Peilong Lai, Jianyu Weng, Chenwei Luo, Rong Guo, Zesheng Lu, Suxia Geng, Xin Du, PhD, Suijing Wu

Blood (2011) 118 (21): 4086.

https://doi.org/10.1182/blood.V118.21.4086.4086

Published: 2011

Journal Articles

Efficacy of Short Oral Leucovorin Rescue (SOLR) In Managing Recurrent Pralatrexate (Folotyn) Induced Mucositis (RPIM) Despite Dose Reduction

Philip A Haddad, MD

Blood (2011) 118 (21): 4745.

https://doi.org/10.1182/blood.V118.21.4745.4745

Published: 2011

Journal Articles

A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma.

Frederick Lansigan, MD, Stuart Seropian, MD, Dennis L. Cooper, MD, Von Potter, MD, Noelle Sowers, RN, Francine M Foss, MD

Blood (2010) 116 (21): 2816.

https://doi.org/10.1182/blood.V116.21.2816.2816

Published: 2010

Journal Articles

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

Madeleine Duvic, MD, Youn H Kim, MD, Timothy M Kuzel, MD, Theresa R Pacheco, MD, Francine M Foss, Sareeta Parker, Syed Rizvi, Cong Chen, Jean Marie Arduino, ScD, Elise A. Olsen, MD

Blood (2009) 114 (22): 1709.

https://doi.org/10.1182/blood.V114.22.1709.1709

Published: 2009

Journal Articles

Assessment of Durability of Response in Patients with Skin Graft Versus Host Disease beyond Six Months Treatment with Extracorporeal Photopheresis: Reduction of Steroid Resistance and Evaluation of Long-Term Therapy on Survival.

Youssef Sorour, Peter C Taylor

Blood (2008) 112 (11): 2217.

https://doi.org/10.1182/blood.V112.11.2217.2217

Published: 2008

Journal Articles

A Randomized Single−Blind Study of Extracorporeal Photopheresis with UVADEX® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD.

Mary E.D. Flowers, MD, Koen Van Besien, MD, Jane Apperley, MD, Andrea Bacigalupo, MD, Ahmet Elmaagacli, MD, Andrew Grigg, MD, Hans-Jochem Kolb, MD, Luis Fernando Bouzas, MD, Mauricette Michallet, MD, Vijay Reddy, MD, Jim Wang, MD, Paul Williamson, MD, Robert Knobler, MD, Hildegard Greinix, MD

Blood (2006) 108 (11): 758.

https://doi.org/10.1182/blood.V108.11.758.758

Published: 2006

Journal Articles

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.

Madeleine Duvic, MD, Francine M. Foss, MD, Elise A. Olsen, MD, Andres Forero-Torres, MD, J. Claude Bennett, MD, Shanta Bantia, PhD, J. Michael Kilpatrick, PhD

Blood (2004) 104 (11): 2491.

https://doi.org/10.1182/blood.V104.11.2491.2491

Published: 2004

NARROW

Leukemia Cutis As an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia

Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome

Phase 1 Trial of Cobomarsen, an Inhibitor of Mir-155, in Cutaneous T Cell Lymphoma

Pirfenidone Reverses Murine Chronic Graft Versus Host Disease

Phase 2 Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Cutaneous T-Cell Lymphoma

Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium

Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL)

Comparison of Proposed NIH Response Criteria with Clinician-Reported Changes in Organ-Specific and Overall Response

Selective Targeting of B Cells with Mesenchymal Stromal Cells Treatment Is An Efficacious Strategy for Cutaneous Cgvhd,

Efficacy of Short Oral Leucovorin Rescue (SOLR) In Managing Recurrent Pralatrexate (Folotyn) Induced Mucositis (RPIM) Despite Dose Reduction

A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma.

The Systemic Effects of Vorinostat in Patients (Pts) with Cutaneous T-Cell Lymphoma (CTCL): Post-Hoc Analyses in Pts with High Blood Tumor Burden.

Assessment of Durability of Response in Patients with Skin Graft Versus Host Disease beyond Six Months Treatment with Extracorporeal Photopheresis: Reduction of Steroid Resistance and Evaluation of Long-Term Therapy on Survival.

A Randomized Single−Blind Study of Extracorporeal Photopheresis with UVADEX® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD.

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only